Validation of the 6 min walk test according to the OMERACT filter: A systematic literature review by the EPOSS-OMERACT group

Annals of the Rheumatic Diseases

Volumn 69, Issue 7, 2010, Pages 1360-1363

  Avouac, Jérôme ^a   Kowal Bielecka, Otylia ^b   Pittrow, David ^c   Huscher, Doerte ^d   Behrens, Frank ^e   Denton, Christopher P ^f   Foeldvari, Ivan ^g   Humbert, Marc ^h   Matucci Cerinic, Marco ⁱ   Nash, Peter ^j   Opitz, Christian F ^k   Rubin, Lewis J ^l   Seibold, James R ^m   Distler, Oliver ⁿ   Furst, Daniel E ^o  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d German Rheumatism Research Centre   (Germany)

^e GOETHE UNIVERSITY   (Germany)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^g Hamburger Zentrum für Kinder und Jugendrheumatologie Kompetenz   (Germany)

^h HÔPITAL ANTOINE BÉCLÈRE   (France)

ⁱ UNIVERSITY OF FLORENCE   (Italy)

^j Rheumatology Research Unit   (Australia)

^k German Red Cross Hospital   (Germany)

^l UNIVERSITY OF CALIFORNIA   (United States)

^m UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

ⁿ UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^o UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COMORBIDITY; CONTENT VALIDITY; DISCRIMINATION LEARNING; FACE VALIDITY; FEASIBILITY STUDY; HEART CATHETERIZATION; HEMODYNAMIC PARAMETERS; HUMAN; LITERATURE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; REPRODUCIBILITY; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; TREATMENT RESPONSE; VALIDITY; WALKING; EXERCISE TEST; METHODOLOGY; REVIEW; VALIDATION STUDY;

EXERCISE TEST; FEASIBILITY STUDIES; HUMANS; HYPERTENSION, PULMONARY; REPRODUCIBILITY OF RESULTS; SCLERODERMA, SYSTEMIC;

EID: 77954991688     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2009.120303     Document Type: Article

References (20)

1. Allanore Y, Avouac J, Wipff J, et al. New therapeutic strategies in the management of systemic sclerosis. Expert Opin Pharmacother 2007;8:607-15. (Pubitemid 46547014)
2. Merkel PA, Clements PJ, Reveille JD, et al. Current status of outcome measure development for clinical trials in systemic sclerosis. Report from OMERACT 6. J Rheumatol 2003;30:1630-47.
3. Distler O, Behrens F, Pittrow D, et al. Defining appropriate outcome measures in pulmonary arterial hypertension related to systemic sclerosis: a Delphi consensus study with cluster analysis. Arthritis Rheum 2008;59:867-75. (Pubitemid 351847571)
4. Boers M, Brooks P, Strand CV, et al. The OMERACT filter for outcome measures in rheumatology. J Rheumatol 1998;25:198-9.
5. Shekelle PG, Woolf SH, Eccles M, et al. Clinical guidelines: developing guidelines. BMJ 1999;318:593-6.
6. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
7. Denton CP, Humbert M, Rubin L, et al. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions. Ann Rheum Dis 2006;65:1336-40. (Pubitemid 44620443)
8. Garin MC, Highland KB, Silver RM, et al. Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol 2009;36:330-6.
9. Schoindre Y, Meune C, Dinh-Xuan AT, et al. Lack of specificity of the 6-minute walk test as an outcome measure for patients with systemic sclerosis. J Rheumatol 2009;36:1481-5.
10. Oudiz RJ, Schilz RJ, Barst RJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest 2004;126:420-7.
11. Villalba WO, Sampaio-Barros PD, Pereira MC, et al. Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients. Chest 2007;131:217-22.
12. Williams MH, Das C, Handler CE, et al. Systemic sclerosis associated pulmonary hypertension: improved survival in the current era. Heart 2006;92:926-32. (Pubitemid 43974055)
13. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000;132:425-34.
14. Girgis RE, Frost AE, Hill NS, et al. Selective endothelin A receptor antagonism with sitaxsentan for pulmonary arterial hypertension associated with connective tissue disease. Ann Rheum Dis 2007;66:1467-72.
15. Badesch DB, Hill NS, Burgess G, et al. Sildenafil for pulmonary arterial hypertension associated with connective tissue disease. J Rheumatol 2007;34:2417-22. (Pubitemid 350230665)
16. Buch MH, Denton CP, Furst DE, et al. Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis 2007;66:169-73.
17. Impens AJ, Wangkaew S, Seibold JR. The 6-minute walk test in scleroderma - how measuring everything measures nothing. Rheumatology (Oxford) 2008;47(Suppl 5):v68-9.
18. Morelli S, Ferrante L, Sgreccia A, et al. Pulmonary hypertension is associated with impaired exercise performance in patients with systemic sclerosis. Scand J Rheumatol 2000;29:236-42. (Pubitemid 32015644)
19. Avouac J, Guerini H, Wipff J, et al. Radiological hand involvement in systemic sclerosis. Ann Rheum Dis 2006;65:1088-92. (Pubitemid 44133273)
20. de Oliveira NC, dos Santos Sabbag LM, Ueno LM, et al. Reduced exercise capacity in systemic sclerosis patients without pulmonary involvement. Scand J Rheumatol 2007;36:458-61.